Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo
A phase 2 trial of FOLFIRI, Bevacizumab, FOLFOX in colorectal cancer, run by Cardiff Oncology, active and no longer recruiting.
Overview
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation is a phase 2 interventional study registered as NCT06106308 by Cardiff Oncology, with 110 participants enrolled, started 2024-02-27 and due to reach its primary completion in 2026-11. Interventions recorded: Onvansertib, FOLFIRI, Bevacizumab, FOLFOX. Conditions listed: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Bevacizumab, Colorectal cancer.
- TrialFOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Colorectal cancer.
- TrialStudy of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Colorectal cancer.
- TrialCOLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Bevacizumab, Colorectal cancer.
- TrialStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Colorectal cancer.
- TrialA Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Colorectal cancer.